Zobrazeno 1 - 10
of 2 086
pro vyhledávání: ''
Publikováno v:
Cancer Causes & Control. 33:1161-1172
Purpose To quantitatively evaluate contributions of trends in incidence, relative survival, and stage at diagnosis to the dynamics in the prevalence of major cancers (lung, prostate, colon, breast, urinary bladder, ovaries, stomach, pancreas, esophag
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:1363-1374
Purpose We aim to assess attitudes toward a COVID-19 vaccine and vaccination status in cancer patients and to explore additional factors such as the level of information and comprehensibility and accessibility of this information, anxiety symptoms in
Autor:
Becky White, Meena Rafiq, Arturo Gonzalez-Izquierdo, Willie Hamilton, Sarah Price, Georgios Lyratzopoulos
Publikováno v:
British Journal of Cancer. 126:1627-1636
Background The management of adults presenting with fatigue presents a diagnostic challenge, particularly regarding possible underlying cancer. Methods Using electronic health records, we examined cancer risk in patients presenting to primary care wi
Publikováno v:
BMC Cancer. 22
Background Cancer is a major public health problem with pharmacotherapy being the cornerstone of its management. Cancer patients receive multiple drugs concurrently risking Drug-Drug Interactions (DDIs). DDIs, though avoidable, can significantly cont
Autor:
Zahra Madjd, Mahdieh Razmi, Sima Saki, Elham Kalantari, Leili Saeednejad Zanjani, Monireh Mohsenzadegan, Fahimeh Fattahi, Maryam Abolhasani
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:609-631
Melanoma-associated antigen A2 (MAGE-A2) is a member of the cancer-testis antigen family differentially overexpressed in a variety of malignancies and is associated with tumor development. However, clinical significance and prognostic value of MAGE-A
Autor:
George Rust, Robert Weech-Maldonado, Ferhat D. Zengul, Josué Patien Epané, Luceta McRoy, Zo Ramamonjiarivelo
Publikováno v:
Cancer Causes & Control. 33:321-329
Cancer incidence in the USA remains higher among certain groups, regions, and communities, and there are variations based on nativity. Research has primarily focused on specific groups and types of cancer. This study expands on previous studies to ex
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Fang Fang Zhang, Mengyuan Ruan, Diane M. Harris, Donatus U. Ekwueme, Dariush Mozaffarian, Jaya S. Khushalani, Frederick Cudhea, Zhilei Shan
Publikováno v:
Cancer Causes Control
Purpose: Suboptimal diet is a preventable cause of cancer. We aimed to estimate the economic burden of diet-associated cancer among US adults. Methods: We used a Comparative Risk Assessment model to quantify the number of new cancer cases attributabl
Autor:
Anna E. Prizment, Sithara Vivek, Heather H. Nelson, Eileen M. Crimmins, Bharat Thyagarajan, Jessica D. Faul
Publikováno v:
Cancer Causes Control
PURPOSE: The higher prevalence of cognitive impairment/ dementia among cancer survivors is likely multifactorial. Since both exposures to cytomegalovirus (CMV) and inflammation are common among elderly cancer survivors, we evaluated their contributio
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.